|Affymetrix Launches Cost-Effective Bovine Genotyping Array for Accurate Trait Selection|
SANTA CLARA, Calif., Jan 12, 2011 (BUSINESS WIRE) --
Affymetrix, Inc. (NASDAQ:AFFX) today announced it has launched the Axiom(TM) Genome-Wide BOS 1 Array, which has 34 percent higher genetic coverage than the current leading array because of its unique design. Developed in conjunction with the Affymetrix Bovine Consortium of leading breeders and researchers worldwide, the array comprehensively covers genetic traits from the most commercially vital breeds of dairy and beef cattle. The Axiom Genome-Wide BOS 1 Array's high-performing markers greatly improve the reliability of genetic profiling by giving breeders an accelerated path to higher quality beef and dairy cattle and reducing the need for costly and time-consuming phenotypic testing.
The Affymetrix Bovine Consortium, including the University of Missouri, U.S. Department of Agriculture's Agricultural Research Service (USDA-ARS), Roslin Institute and ARK-Genomics, University of Edinburgh, Technical University of Munich, and University of Liverpool, among others, sequenced genomic DNA from a variety of Bos taurus and Bos indicus breeds, including Holstein, Angus, Nelore, and Gir, to discover 46 million potential single nucleotide polymorphisms (SNPs). Approximately 400 samples from 20 diverse breeds were used to screen millions of these SNPs to identify 3 million high-performing, validated polymorphic SNPs. Finally, a subset of more than 648,000 SNPs was selected using a novel array design process that maximizes genetic coverage and minimizes redundancy for cost-effective genotyping.
"We're proud to be a part of a highly successful collaboration and that our new genetic profiling application will generate enormous value for breeders in terms of expense and time savings," said Kevin King, Affymetrix President and CEO. "We're hearing from our collaborators that our array is setting a new standard for cattle genotyping because it supplies what other options lack--maximum genetic coverage for an affordable price."
Three million validated SNPs comprise the newly launched Axiom Bovine Genomic Database, which has supplied many Affymetrix Bovine Consortium members with data obtained from their samples. Now, the database is available to all breeders and researchers who also want to design their own customized arrays through the Axiom myDesign(TM) Genotyping Array service.
Neogen Corporation's (NASDAQ:NEOG) subsidiary GeneSeek(R), a global provider of DNA testing for farm animal improvement and veterinary diagnostic testing and surveillance, will be among the first to offer Axiom Genotyping Solution services to the bovine community using the GeneTitan(R) System.
"Since 1998, GeneSeek has been providing comprehensive solutions and services for the agricultural biotechnology industry," said Andy Last, Chief Commercial Officer at Affymetrix. "We are excited to see GeneSeek evaluating our platform to better serve its worldwide customers who are increasingly seeing the importance of using genotyping in their breeding process."
Affymetrix technology is used by the world's top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and nonprofit research institutes. More than 2,000 systems have been shipped around the world and more than 22,000 peer-reviewed papers have been published using the technology.
Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Santa Clara, Cleveland, Ohio, and Singapore. The company has about 1,000 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit http://www.affymetrix.com.
All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies" or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected. These and other risk factors are discussed in Affymetrix' Form 10-K for the year ended December 31, 2009, and other SEC reports for subsequent quarterly periods.
NOTE: Affymetrix, the Affymetrix logo, Axiom, Axiom MyDesign and GeneTitan System are trademarks or registered trademarks of Affymetrix Inc.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6570424&lang=en
SOURCE: Affymetrix, Inc.
|Data provided by Nasdaq. Minimum 15 minutes delayed.|